A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 15, Issue 4, Pages 493-501
Publisher
Informa Healthcare
Online
2016-01-23
DOI
10.1517/14740338.2016.1145653
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease
- (2015) T. Lobatón et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice
- (2015) W. Moon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases
- (2015) K. Papamichael et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study
- (2015) D. Pugliese et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cumulative Incidence of, Risk Factors for and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience
- (2015) Estelle Fréling et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease
- (2015) Isabelle Cleynen et al. ANNALS OF INTERNAL MEDICINE
- The Impact of Preoperative Serum Anti-TNFα Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery
- (2015) Cheryl Lau et al. ANNALS OF SURGERY
- Anti-TNF therapy for paediatric IBD: the Scottish national experience
- (2015) F L Cameron et al. ARCHIVES OF DISEASE IN CHILDHOOD
- Effectiveness and Safety of Immunomodulators With Anti–Tumor Necrosis Factor Therapy in Crohn’s Disease
- (2015) Mark T. Osterman et al. Clinical Gastroenterology and Hepatology
- Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials
- (2015) Jennifer L. Jones et al. Clinical Gastroenterology and Hepatology
- Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease
- (2015) Lauren A. George et al. DIGESTIVE DISEASES AND SCIENCES
- Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis
- (2015) Fan Wang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events
- (2015) Reena Khanna et al. Expert Opinion On Drug Safety
- Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment
- (2015) Johannan F. Brandse et al. Journal of Crohns & Colitis
- DOP036. PYRAMID registry: an observational study of adalimumab in Crohn's disease: Results at year 6
- (2015) Journal of Crohns & Colitis
- European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
- (2015) Vito Annese et al. Journal of Crohns & Colitis
- Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study
- (2015) C. Coutzac et al. Journal of Crohns & Colitis
- Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
- (2015) Reena Khanna et al. LANCET
- A Study Investigating the Association of Dermatological and Infusion Reactions to Infliximab and Infliximab Trough Levels
- (2015) Vivian Wai-Mei Huang et al. Canadian Journal of Gastroenterology and Hepatology
- 865 PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes in Women With IBD Exposed to Immunomodulators and Biologic Therapy
- (2015) Uma Mahadevan et al. GASTROENTEROLOGY
- Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study
- (2014) W. J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease
- (2014) P. Deepak et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease
- (2014) M. Seirafi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease
- (2014) C. J. M. Williams et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
- (2014) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Risks of Serious Infection or Lymphoma With Anti–Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic Review
- (2014) Parambir S. Dulai et al. Clinical Gastroenterology and Hepatology
- How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?
- (2014) María Chaparro et al. Expert Opinion On Drug Safety
- Safety considerations when using anti-TNFα therapy to treat Crohn’s disease
- (2014) Cristiano Pagnini et al. Expert Opinion On Drug Safety
- Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy
- (2014) Nabeel Khan et al. Expert Opinion On Drug Safety
- Anti–Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD
- (2014) Parambir S. Dulai et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs
- (2014) S Mozaffari et al. HUMAN & EXPERIMENTAL TOXICOLOGY
- Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease
- (2014) Neeraj Narula et al. INFLAMMATORY BOWEL DISEASES
- Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease
- (2014) Nynne Nyboe Andersen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- DOP099 Five-year safety results from the ENCORE registry: Malignancies in patients with Crohn's disease treated with infliximab, standard therapy, or switched from standard therapy to infliximab
- (2014) G. D'Haens et al. Journal of Crohns & Colitis
- High-Dose Infliximab Therapy in Crohn's Disease: Clinical Experience, Safety, and Efficacy
- (2014) S. A. Hendler et al. Journal of Crohns & Colitis
- Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
- (2014) J.F. Rahier et al. Journal of Crohns & Colitis
- Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
- (2013) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis
- (2013) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Targeting TNF-α for the treatment of inflammatory bowel disease
- (2013) Thomas Billiet et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Drug safety evaluation of certolizumab pegol
- (2013) Marc Ferrante et al. Expert Opinion On Drug Safety
- Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease
- (2013) Mark T. Osterman et al. GASTROENTEROLOGY
- Ten Years of Infliximab for Crohn’s Disease
- (2013) Emma J. Eshuis et al. INFLAMMATORY BOWEL DISEASES
- Biological Therapy in a Pediatric Crohn Disease Population at a Referral Center
- (2013) Federica Nuti et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review
- (2013) Renée M Marchioni WORLD JOURNAL OF GASTROENTEROLOGY
- A Pooled Analysis of Infections, Malignancy and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study
- (2012) Parakkal Deepak et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
- (2012) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
- (2012) Christina Ha et al. Clinical Gastroenterology and Hepatology
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
- (2012) Uma Mahadevan et al. Clinical Gastroenterology and Hepatology
- Infliximab for Crohn’s Disease: The First 500 Patients Followed Up Through 2009
- (2012) Jennifer L. Seminerio et al. DIGESTIVE DISEASES AND SCIENCES
- Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease
- (2012) Millie D. Long et al. GASTROENTEROLOGY
- Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease
- (2012) Amit Assa et al. Journal of Crohns & Colitis
- Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening
- (2012) Aranzazu Jauregui-Amezaga et al. Journal of Crohns & Colitis
- Risk of Infection and Prevention in Pediatric Patients With IBD
- (2012) Gigi Veereman-Wauters et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Paradoxical inflammation induced by anti-TNF agents in patients with IBD
- (2012) Isabelle Cleynen et al. Nature Reviews Gastroenterology & Hepatology
- Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease
- (2012) Åse Riis et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature
- (2011) G. Cullen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease
- (2011) Lisa J Herrinton et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
- (2011) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease
- (2011) Laurent Peyrin–Biroulet et al. GASTROENTEROLOGY
- Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy
- (2011) Fabian Schnitzler et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
- (2011) Mamoru Watanabe et al. Journal of Crohns & Colitis
- Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti–Tumor Necrosis Factor Therapy
- (2010) Jean–François Rahier et al. Clinical Gastroenterology and Hepatology
- Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease
- (2010) Mario Cottone et al. Clinical Gastroenterology and Hepatology
- A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
- (2010) David S. Kotlyar et al. Clinical Gastroenterology and Hepatology
- Adalimumab for Crohnʼs disease in clinical practice at Mayo clinic: The first 118 patients
- (2010) Jason M. Swoger et al. INFLAMMATORY BOWEL DISEASES
- Cancer in Crohnʼs Disease patients treated with infliximab: A long-term multicenter matched pair study
- (2010) Livia Biancone et al. INFLAMMATORY BOWEL DISEASES
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
- (2009) G. R. LICHTENSTEIN et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn’s Disease
- (2009) Joel R Rosh et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease
- (2009) Josh Marehbian et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
- (2009) Corey A. Siegel et al. Clinical Gastroenterology and Hepatology
- Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease
- (2009) Millie D. Long et al. Clinical Gastroenterology and Hepatology
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Adalimumab safety in global clinical trials of patients with Crohnʼs disease
- (2009) Jean-Frédéric Colombel et al. INFLAMMATORY BOWEL DISEASES
- Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
- (2009) Laurent Beaugerie et al. LANCET
- The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up
- (2008) C. W. LEES et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
- (2008) Laurent Peyrin–Biroulet et al. Clinical Gastroenterology and Hepatology
- Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
- (2008) Murat Toruner et al. GASTROENTEROLOGY
- Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
- (2008) H Fidder et al. GUT
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started